Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 12/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424637 | 0.85 | GAA (0.49) | SMYD3GAAMAPTTDP1PKM | |
| SCHEMBL2203244 | 0.82 | GAA (0.64) | SMYD3GAAMAPTTDP1PKM | |
| Hydrochloric Acid SCHEMBL28865546 | 0.81 | GAA (0.62) | SMYD3GAAMAPTTDP1PKM | |
| Dimethylformamide SCHEMBL27577776 | 0.78 | GAA (0.53) | GAAMAPTTDP1PKMKMT2A | |
| SCHEMBL6424640 | 0.78 | SIGMAR1 (0.53) | SMYD3MAPTTDP1PKMKMT2A | |
| SCHEMBL6423157 | 0.78 | GAA (0.57) | SMYD3GAATDP1KMT2AMEN1 | |
| SCHEMBL6602558 | 0.74 | GAA (0.57) | SMYD3GAAMAPTTDP1PKM | |
| SCHEMBL6523246 | 0.74 | AHR (0.47) | SMYD3GAA | |
| SCHEMBL6423152 | 0.72 | GAA (0.56) | SMYD3GAATDP1KMT2AMEN1 | |
| SCHEMBL1556955 | 0.71 | GAA (0.60) | SMYD3GAAMAPTTDP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1427326-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Sugen, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |